145 related articles for article (PubMed ID: 36595566)
1. Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Bruno R; Marchand M; Yoshida K; Chan P; Li H; Zou W; Mercier F; Chanu P; Wu B; Lee A; Li C; Jin JY; Maitland ML; Reck M; Socinski MA
Clin Cancer Res; 2023 Mar; 29(6):1047-1055. PubMed ID: 36595566
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
4. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N; Barlesi F; Socinski MA; Reck M; Thomas CA; Cappuzzo F; Mok TSK; Finley G; Aerts JG; Orlandi F; Moro-Sibilot D; Jotte RM; Stroyakovskiy D; Villaruz LC; Rodríguez-Abreu D; Wan-Teck Lim D; Merritt D; Coleman S; Lee A; Shankar G; Yu W; Bara I; Nishio M
J Thorac Oncol; 2022 Feb; 17(2):309-323. PubMed ID: 34626838
[TBL] [Abstract][Full Text] [Related]
5. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
[No Abstract] [Full Text] [Related]
6. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
[TBL] [Abstract][Full Text] [Related]
8. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Socinski MA; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kong S; Lee A; Coleman S; Zou W; McCleland M; Shankar G; Reck M
J Thorac Oncol; 2021 Nov; 16(11):1909-1924. PubMed ID: 34311108
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
[TBL] [Abstract][Full Text] [Related]
10. Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.
Shemesh CS; Chan P; Marchand M; Gonçalves A; Vadhavkar S; Wu B; Li C; Jin JY; Hack SP; Bruno R
Clin Pharmacol Ther; 2023 Sep; 114(3):644-651. PubMed ID: 37212707
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
Chan P; Marchand M; Yoshida K; Vadhavkar S; Wang N; Lin A; Wu B; Ballinger M; Sternheim N; Jin JY; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1171-1182. PubMed ID: 34270868
[TBL] [Abstract][Full Text] [Related]
13. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Reck M; Wehler T; Orlandi F; Nogami N; Barone C; Moro-Sibilot D; Shtivelband M; González Larriba JL; Rothenstein J; Früh M; Yu W; Deng Y; Coleman S; Shankar G; Patel H; Kelsch C; Lee A; Piault E; Socinski MA
J Clin Oncol; 2020 Aug; 38(22):2530-2542. PubMed ID: 32459597
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.
An MW; Han Y; Meyers JP; Bogaerts J; Sargent DJ; Mandrekar SJ
J Clin Oncol; 2015 Dec; 33(34):4048-57. PubMed ID: 26503199
[TBL] [Abstract][Full Text] [Related]
15. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
Socinski MA; Jotte RM; Cappuzzo F; Nishio M; Mok TSK; Reck M; Finley GG; Kaul MD; Yu W; Paranthaman N; Bara I; West HJ
JAMA Oncol; 2023 Apr; 9(4):527-535. PubMed ID: 36795388
[TBL] [Abstract][Full Text] [Related]
16. Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches.
Marchand M; Gonçalves A; Mercier F; Chanu P; Jin JY; Guedj J; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; ():. PubMed ID: 38629452
[TBL] [Abstract][Full Text] [Related]
17. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.
Gonçalves A; Marchand M; Chan P; Jin JY; Guedj J; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):68-78. PubMed ID: 37877248
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
20. External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data.
Kassir N; Chan P; Dang S; Bruno R
Cancer Chemother Pharmacol; 2023 Sep; 92(3):205-210. PubMed ID: 37410154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
